Ebglyss is used to treat moderate-to-severe atopic dermatitis. It addresses the inflammation caused by eczema all over your body, resulting in persistently dry, itchy, and irritated skin.
Approval Date
13-Sep-24
Data Exclusivity Expiry
13-Sep-28
Market Exclusivity Expiry
13-Sep-36
Commercial snapshot
Market performance & projections
Revenue ($M)
533
CAGR (%)
40.77%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
884
2027
1,267
2028
1,696
2029
2,093
2030
2,436
2031
2,737
2032
3,009
Molecule profile
Details & specifications
Molecule
Lebrikizumab-Lbkz
Innovator
ELI LILLY
Dosage Form
Prefilled Pen Subcutaneous Injection
Strength
250 mg
Therapeutic Category
Immunomodulators
Usage
To treat moderate-to-severe atopic dermatitis
Good to know
Frequently asked questions
Ready to act on this opportunity?
Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.